San Deigo, CA, April, 30th, 2012 Dr. Eyitayo S. Fakunle joins CalAsia Pharmaceuticals as Head of Translational Research. CalAsia Pharmaceuticals appoints Dr. Eyitayo “Tayo” Fakunle as head of translational research. Dr. Tayo brings in vast experience and background to CalAsia, including stem-cell technology, analytical chemistry, public health and engineering. We are delighted to have Dr. Tayo join CalAsia, her experience in stem-cell technology and its use for evaluating our lead drug candidates to establish proof of concept in disease derived human induced pluripotent stem cells (iPSC) will allow to rapidly transition our drug discovery programs into preclinical and clinical development studies said Dr. Sridhar Prasad, Vice President of Research. Dr. Tayo added, I am excited to join CalAsia, the use of innovative drug discovery technologies at CalAsia including differential fragment screening and structure based lead optimization when combined with iPSC based screening of drug candidates will expedite in advancing them for evaluating in patient population. Dr. Tayo received her PhD from the University of Arkansas, Fayetteville, Arkansas. She conducted her postdoctoral training at the University of California San Diego, La Jolla; Department of bioengineering followed by The Scripps research Institute, and Center for Regenerative Medicine, La Jolla CA. Dr. Tayo is recipient of Under Forty Inspired Leaders of Tomorrow, San Diego County Urban League award, United Negro College Fund/Merck Postdoctoral Fellowship and Bill and Melinda Gates Grand Challenge in Global Health Explorations Award. She has co-authored multiple publications and presented at numerous national and international scientific meetings.
About CalAsia Pharmaceuticals:
CalAsia Pharmaceuticals, Inc. is a privately held early stage pharmaceutical company focused on the rapid discovery of drug-like small molecules by utilizing its core technologies. In detail, CalAsia core technologies combine functional fragment screening with X-ray crystallography co-crystallization to rationally design and synthesize New Chemical Entities (NCEs) with drug-like properties. By differential fragment screening of closely related isotypes, CalAsia also develops selective NCEs early in the drug discovery process thereby increasing the quality of potential drug candidates. Currently, CalAsia has several drug-discovery programs for the treatment unmet medical needs for CNS, metabolic, inflammation, and infectious diseases. Prostate Cancer and Malaria. Of note, the CalAsia team has decades of drug-discovery experience and has been involved in numerous drug-discovery programs that have resulted in multiple clinical candidates as well as one marketed drug.
CalAsia’s Services:
The CalAsia team provides its expertise; which includes cloning, recombinant protein expression (E. coli, Baculovirus & Yeast), recombinant protein purification, biochemical assays, cellular assays, fragment screening, and X-ray crystallography co-crystallization; to the drug discovery community through contract research.
